We report a case of DKA secondary to new‐onset T1DM in a patient with malignant mesothelioma being treated with nivolumab, a PD‐1 inhibitor, and ipilimumab, a CTLA‐4 inhibitor. The gene discussed is CTLA4; the disease is type 1 diabetes mellitus.